pargyline has been researched along with dopamine quinone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baranyi, M; Chai, CL; Dunkel, P; Frau, L; Gölöncsér, F; Huleatt, PB; Khoo, ML; Kittel, Á; Kulcsár, S; Mátyus, P; Morelli, M; Otrokocsi, L; Pinna, A; Porceddu, PF; Sperlágh, B | 1 |
1 other study(ies) available for pargyline and dopamine quinone
| Article | Year |
|---|---|
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Rats, Wistar; Substantia Nigra | 2016 |